Skip to main content
. 2021 Oct 18;12:754436. doi: 10.3389/fimmu.2021.754436

Table 4.

Summary of actively recruiting clinical trials evaluating radiotherapy in combination with immune checkpoint inhibition.

Target Checkpoint inhibitor Number of actively recruiting clinical trials
CTLA-4 Ipilimumab 51
PD-1 Nivolumab 138
Pembrolizumab 161
Cemiplimab 6
Dostarlimab 3
PDL-1 Atezolizumab 59
Durvalumab 115
Avelumab 23